Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

BACKGROUND: Anti-PD1/PD-L1 monoclonal antibodies (mAbs) increase overall survival compared to standard of care (SOC) in different tumors. However, a proportion of patients (pts) will have progressive disease (PD) as best response. We conducted a meta-analysis to study the rates of response comparing...

Descripción completa

Detalles Bibliográficos
Autores principales: Carretero-González, Alberto, Lora, David, Ghanem, Ismael, Zugazagoitia, Jon, Castellano, Daniel, Sepúlveda, Juan M., López-Martin, José A., Paz-Ares, Luis, de Velasco, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823578/
https://www.ncbi.nlm.nih.gov/pubmed/29492229
http://dx.doi.org/10.18632/oncotarget.24283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823578/
https://www.ncbi.nlm.nih.gov/pubmed/29492229
http://dx.doi.org/10.18632/oncotarget.24283

Ejemplares similares